Dr. Reddy’s Laboratories Limited reported Total Income for Q4 FY23 of ₹6,453.7 Crore up from ₹5,596.8 Crore year on year, a growth of 15.3%. Consolidated Net Profit of ₹960.1 Crore, surged from ₹97 Crore in the same quarter of the previous year. The Earnings per Share is ₹57.68, from ₹5.83 in the same quarter of […]
Dr. Reddy’s Laboratories Limited is an Indian multinational pharmaceutical company with a presence in over 25 countries. It was founded in 1984 and has its headquarters in Hyderabad, India. Dr. Reddy’s is a research-driven company with a focus on developing and manufacturing high-quality pharmaceutical products. The company operates in three main segments: Global Generics, Pharmaceutical […]
About Company: Founded in 1984 and headquartered in Hyderabad, India, Dr Reddy’s Laboratories (DRL) is India’s second largest pharma company by global revenues. With more than ~20,000 employees, 1,200 scientists, 350 Ph.D.’s and an amazing portfolio, the company has been known for its mind-blowing R&D. DRL offers a portfolio of products and services, including Active […]
Revenue for Q1 FY23 has increased by 6% YoY to ₹ 52,154 millions. Profits have grown by 108% YoY to ₹ 11,876 millions because Other Income has grown by 691% YoY to ₹ 8,539 millions from ₹ 1,079 millions. In this quarter’s results, it was visible that the drastic increase in Other Income is the reason […]
Dr. Reddy’s Laboratories(NSE:DRREDDY) recently reported its second-quarter 2022 earnings results. The company had a consolidated revenue of ₹5,992 crores with a growth of 20 % year on year. Dr Reddy’s lab had a net profit of ₹964 crores or ₹59.88 per share compared to ₹781 crores or ₹46.40 per share in the same quarter of […]
Dr Reddy’s Laboratories (NSE: DRREDDY) reported its second-quarter financial results for the period ended September 30, 2021. The company had total revenue of ₹57.6 billion with a growth of 18% year on year. Dr Reddy’s reported a net profit of ₹9.92 billion or ₹59.65 per share compared to ₹7.62 billion or ₹45.83 in the same […]
Dr. Reddy’s Laboratories (NSE: DRREDDY) Q2 2025 Earnings Call dated Nov. 05, 2024 Corporate Participants: Richa Periwal — Head of IR M. V. Narasimham — CFO Erez Israeli — CEO Analysts: Kunal Dhamesha — Analyst Neha Manpuria — Analyst Amey Chalke — Analyst Mikaela Franceschina — Analyst Harith Ahamed — Analyst Damayanti Kerai — Analyst […]
Dr. Reddy’s Laboratories (NSE: DRREDDY) Q3 2025 Earnings Call dated Jan. 23, 2025 Corporate Participants: Richa Periwal — Head, Investor Relations & Corporate Analytics M V Narasimham — Chief Financial Officer Erez Israeli — Chief Executive Officer Analysts: Kunal Dhamesha — Analyst Neha Manpuria — Analyst Amey Chalke — Analyst Bino Pathiparampil — Analyst Surya […]
Dr. Reddy’s Laboratories (NSE: DRREDDY) Q4 2025 Earnings Call dated May. 09, 2025 Corporate Participants: Richa Periwal — Head, Corporate Analytics, Corporate Strategy and Investor Relations M V Narasimham — Chief Financial Officer Erez Israeli — Chief Executive Officer Unidentified Speaker Analysts: Neha Manpuria — Analyst Kunal Dhamesha — Analyst Madhav Marda — Analyst Amey […]
Dr. Reddy’s Laboratories (NSE: DRREDDY) Q1 2026 Earnings Call dated Jul. 23, 2025 Corporate Participants: Aishwarya Sitharam — Investor Relations Richa Periwal — Head of Investor Relations M.V. Narasimham — Chief Financial Officer Erez Israeli — Chief Executive Officer Analysts: Amey Chalke — Analyst Neha Manpuria — Analyst Damayanti Kerai — Analyst Madhav Marda — […]